In today's world, Sultopride has gained unprecedented relevance. Whether in the professional, academic or personal sphere, Sultopride has become a topic of common interest for people of all ages and backgrounds. As society advances, the challenges related to Sultopride become more complex, and the need to understand its implications becomes increasingly pressing. In this article, we will explore different aspects of Sultopride and its impact on various areas of daily life. From its history to its current applications, we will address the many facets of Sultopride and its influence on modern society.
![]() | |
Clinical data | |
---|---|
Trade names | Barnetil, Barnotil, Topral |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, IM |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 3–5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.293 |
Chemical and physical data | |
Formula | C17H26N2O4S |
Molar mass | 354.47 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[2][3][4] It was launched by Sanofi-Aventis in 1976.[2] Sultopride acts as a selective D2 and D3 receptor antagonist.[5] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[6]
Site | Ki | Species | Ref |
---|---|---|---|
D2 | 1.6 | Human | [7] |
D3 | 3.8 | Human | [7] |